Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > When is phase III trial going to start?

<< Previous

Bullboard Posts

Next >>

Comment by Bookworm28on Jun 04, 2021 2:57pm

153 Views

Post# 33331261

RE:When is phase III trial going to start?

...sorry, the Co also said last year.... " while at the same time expeditiously moving forward with phase III development. This parallel strategy is important, as partnering outreach and execution are an extensive, involved process, and the continued advancement of the drug's development program is expected to increase market value and negotiating leverage."

So phase III appears to be a priority. I suppose COVID messed up their plans more than anything else.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China